Lemstra A W, Eikelenboom P, van Gool W A
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Neurologie, Postbus 22.660, 1100 DD Amsterdam.
Ned Tijdschr Geneeskd. 2003 Nov 8;147(45):2201-3.
Cholinesterase inhibitors are licensed for the treatment of dementia in Alzheimer's disease. In clinical practice, these drugs have little effect on the cognitive symptoms of dementia. Several studies report a beneficial effect of cholinesterase inhibitors on neuropsychiatric symptoms. We hypothesise that symptoms such as the impairment of attention and concentration, anxiety, restlessness and hallucinations, delineate a specific central cholinergic deficiency syndrome. It is postulated that this syndrome crosses boundaries of nosological entities and occurs in various neurodegenerative diseases. Symptoms resulting from cholinergic deficiency might be a much better target for treatment than cognitive deficits.
胆碱酯酶抑制剂被批准用于治疗阿尔茨海默病中的痴呆症。在临床实践中，这些药物对痴呆症的认知症状几乎没有效果。几项研究报告了胆碱酯酶抑制剂对神经精神症状的有益作用。我们假设，诸如注意力和专注力受损、焦虑、烦躁不安和幻觉等症状，描绘了一种特定的中枢胆碱能缺乏综合征。据推测，这种综合征跨越了疾病分类实体的界限，发生在各种神经退行性疾病中。胆碱能缺乏引起的症状可能比认知缺陷更适合作为治疗靶点。
